Clinical Trial Update: Biomarker-based Trial of NPC-1 for Alzheimer's Pathology [Phase 1, Phase 2]

View source ↗

Summary

Massachusetts General Hospital is conducting a Phase 1/2 biomarker-based trial of NPC-1 for Alzheimer's pathology, currently recruiting in Alzheimer's disease, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment
• Subjective Cognitive Decline

Drugs mentioned

• NPC-1

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Alzheimer Disease, Mild Cognitive Impairment (MCI) | Phase 1, Phase 2 | Status: RECRUITING